Did Neuralink or another Elon Musk company develop a treatment for stress urinary incontinence?

1. What Neuralink says it does — and what its public pages omit

Neuralink’s official update and clinical trials pages present the company as working on brain–computer interface research and human trials; those pages make no public claim of developing bladder or urinary‑continence treatments ^{[1] [2]}. Available sources do not mention Neuralink funding, announcing, or piloting SUI therapies.

2. Recent, documented SUI innovations are coming from urology and med‑tech companies

Journaled and press reports from 2024–2025 describe new neuromodulation and implant approaches for urinary incontinence: Johns Hopkins describes a patient‑controlled ankle bracelet that delivers tibial‑nerve stimulation for bladder overactivity (a form of neuromodulation) available to patients locally ^[3]. Separately, Neuspera won FDA approval for an integrated sacral neuromodulation system for urinary urge incontinence after the SAN‑UUI trial — a company and device explicitly tied to urology, not to Elon Musk’s firms ^[4].

3. Academic and biotech pipelines show multiple SUI avenues — again, no Musk links

The SUI research landscape in 2025 spans biodegradable scaffolds, tissue‑engineering, cell‑based regeneration and laser or sling surgical innovations; PubMed reviews and narrative reviews document candidates and trials from academic groups and biotechs ^{[6] [7] [8]}. A biotech, MUVON, reported positive Phase 2 results for a muscle precursor cell therapy for SUI in late 2025 — this is a healthcare industry development unconnected to Musk’s companies in available reports ^[5].

4. Why confusion might arise: neurotech, neuromodulation and high‑profile entrepreneurs

The overlap in language — “neurotech,” “neuromodulation,” and “clinical trials” — can create false associations between companies in adjacent fields. Neuralink’s work on brain interfaces and other firms’ neuromodulation devices both sit under the broad neurology umbrella, but available sources show different organizations leading SUI device approvals and trials ^{[1] [4] [3]}.

5. What the reporting actually documents about mechanisms and devices

Johns Hopkins describes a tibial‑nerve‑stimulation bracelet worn around the ankle, delivering twice‑daily 30‑minute sessions that “downregulate” overactive bladder signals — a non‑surgical, patient‑controlled neuromodulation option ^[3]. Neuspera’s percutaneous sacral neuromodulation system is battery‑free and miniaturized and was supported by phase 2 trial results leading to FDA approval for urgency urinary incontinence ^[4]. Academic papers describe alternatives: biodegradable scaffolds, non‑ablative lasers, and adjustable continence implants with long‑term follow‑ups ^{[6] [7] [9]}.

6. Limitations of current reporting and unanswered questions

Available sources do not mention any Elon Musk company developing SUI treatments or partnering publicly on them; they also do not cover private or undisclosed projects that could exist outside public statements ^{[1] [2]}. If a Musk company had a covert program, current reporting would not capture it — but the public and peer‑reviewed record contains no evidence linking Neuralink or Musk’s other firms to SUI therapies ^{[1] [2]}.

7. Bottom line for someone tracking who makes SUI treatments

At present, leadership in new SUI treatments is documented among urology centers, dedicated med‑tech companies (Neuspera), academic groups and emerging biotechs (Johns Hopkins reporting; Neuspera approvals; MUVON and academic trials), not among Elon Musk’s companies, per the available sources ^{[3] [4] [5]}. Claims tying Neuralink or other Musk firms to SUI treatments are not supported by the documents provided here ^{[1] [2]}.